Cited 8 times in
TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-03-10T01:24:24Z | - |
dc.date.available | 2023-03-10T01:24:24Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193154 | - |
dc.description.abstract | Background: T-cell factor 1 (TCF1)+Programmed cell death-1 (PD-1)+ tumour-infiltrating lymphocytes (TILs) are a recently defined subset of exhausted T-cells (Texh-cells) that exhibit a progenitor phenotype. They have been associated with a response to immune checkpoint inhibitor (ICI) therapy in murine tumour models and in patients with malignant melanoma. We investigated the significance of TCF1+PD-1+ TILs as a predictive biomarker for ICI therapy response in non-small-cell lung cancer (NSCLC). Methods: Two different cohorts of NSCLC patients treated with ICI targeting the PD-1/PD-L1 pathway were included. RNA-seq was performed using NSCLC tissues obtained from 234 patients prior to immunotherapy (RNA-seq cohort). Double immunostaining of TCF1 and PD-1 and single immunostaining of other immunologic markers were performed in resected tumour tissues from another 116 patients (immunohistochemistry cohort). Results: In the RNA-seq cohort, both Texh-cell and progenitor Texh-cell gene sets were enriched in responders compared with non-responders. Larger Texh-cell fractions and increased progenitor Texh-cell gene sets were significantly associated with better progression-free survival (PFS). In the immunohistochemistry cohort, the TCF1+PD-1+ TIL number and PD-L1 tumour proportion score were significantly higher in responders than in non-responders. A high number of TCF1+PD-1+ TILs was significantly associated with both PFS and overall survival (OS) after ICI therapy, and it independently predicted a better PFS and OS according to multivariate analysis. Conclusion: TCF1+PD-1+ TILs, representing progenitor Texh-cells, predict both better response and survival in NSCLC patients after ICI therapy. Thus, they may be a useful predictive biomarker for ICI therapy in NSCLC. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier Science Ltd | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Animals OR B7-H1 Antigen / metabolism | - |
dc.subject.MESH | CD8-Positive T-Lymphocytes | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / pathology | - |
dc.subject.MESH | Hepatocyte Nuclear Factor 1-alpha / metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immune Checkpoint Inhibitors / therapeutic use | - |
dc.subject.MESH | Lung Neoplasms* / pathology | - |
dc.subject.MESH | Lymphocytes, Tumor-Infiltrating | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Programmed Cell Death 1 Receptor / metabolism | - |
dc.title | TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학교실) | - |
dc.contributor.googleauthor | Jaemoon Koh | - |
dc.contributor.googleauthor | Sehui Kim | - |
dc.contributor.googleauthor | Yeon Duk Woo | - |
dc.contributor.googleauthor | Seung Geun Song | - |
dc.contributor.googleauthor | Jeemin Yim | - |
dc.contributor.googleauthor | Bogyeong Han | - |
dc.contributor.googleauthor | Sojung Lim | - |
dc.contributor.googleauthor | Hyun Kyung Ahn | - |
dc.contributor.googleauthor | Seungchan Mun | - |
dc.contributor.googleauthor | Jung Sun Kim | - |
dc.contributor.googleauthor | Bhumsuk Keam | - |
dc.contributor.googleauthor | Young A Kim | - |
dc.contributor.googleauthor | Se-Hoon Lee | - |
dc.contributor.googleauthor | Yoon Kyung Jeon | - |
dc.contributor.googleauthor | Doo Hyun Chung | - |
dc.identifier.doi | 10.1016/j.ejca.2022.07.004 | - |
dc.relation.journalcode | J00809 | - |
dc.identifier.eissn | 1879-0852 | - |
dc.identifier.pmid | 35970031 | - |
dc.subject.keyword | Exhausted T cells | - |
dc.subject.keyword | Immune checkpoint inhibitor | - |
dc.subject.keyword | Immunotherapy | - |
dc.subject.keyword | Non-small cell lung cancer | - |
dc.subject.keyword | PD-1 | - |
dc.subject.keyword | Precursor exhausted T cells | - |
dc.subject.keyword | Predictive biomarker | - |
dc.subject.keyword | TCF1 | - |
dc.subject.keyword | Tumor microenvironment | - |
dc.citation.volume | 174 | - |
dc.citation.startPage | 10 | - |
dc.citation.endPage | 20 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, Vol.174 : 10-20, 2022-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.